InterCure Ltd. has called an Extraordinary General Meeting of Shareholders for August 11, 2026, to vote on a proposed 5-to-1 reverse share split. The split is intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as the company received a deficiency notice on February 25, 2026. The Board of Directors unanimously recommends approval of the proposal. InterCure Ltd. is a medical device company that develops and manufactures products for the treatment of benign prostatic hyperplasia (BPH).
